ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 369

Opioid Prescriptions and Adverse Reactions in Children and Adolescents without Serious Diseases

Cecilia P. Chung1, S. Todd Callahan2, William Cooper2, William Dupont3, Katherine Murray1, Kathi Hall4, Judith A. Dudley4, C. Michael Stein1 and Wayne Ray4, 1Medicine, Vanderbilt University Medical Center, Nashville, TN, 2Pediatrics, Vanderbilt University Medical Center, Nashville, TN, 3Biostatistics, Vanderbilt University Medical Center, Nashville, TN, 4Health Policy, Vanderbilt University Medical Center, Nashville, TN

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: opioids, pain, pain management and pediatrics

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2016

Title: Pain – Basic and Clinical Aspects - Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:  There is a well-described epidemic of deaths and hospitalizations related to opioid prescriptions in adults. However, little is known about opioid toxicity in children. We investigated the incidence of opioid toxicity and compared the safety of the most frequently prescribed opioid, codeine, to that of other opioids used by children and adolescents without serious diseases.

Methods:  We studied a Tennessee Medicaid cohort of 424,382 children aged 2–17 years, who filled 1,133,089 opioid prescriptions for non-cancer pain. We excluded children with prior encounters indicating serious diseases (cancer, sickle cell anemia, congenital anomalies, hospitalization for a total of more than 30 days in the preceding year, or history of organ transplant), institutional residence, and history of drug abuse. The primary study endpoint was opioid toxicity, defined as an emergency department visit, hospitalization, or death attributed to opioid analgesic use. Medical records were reviewed to adjudicate the outcomes.

Results:  The median length of opioid prescription was three days. Most prescriptions were for acute, self-limited conditions including dental procedures (31%), outpatient procedure/surgery (24%), trauma (18%), and minor infections (17%). There were 365 confirmed cases of opioid toxicity with a median follow-up time of opioid exposure of 17 days. At 17 days, the cumulative incidence of opioid toxicity was 33.2/100,000 prescriptions. Children taking any opioid at doses in the highest tertile had higher risk of toxicity than those in the lowest tertile (IRR=1.85, 95% CI=1.36-2.51). The use of tramadol [incident rate ratio (IRR)=3.03, 95% confidence interval (CI)=2.0-4.60] and oxycodone (IRR=1.87, 95% CI=1.19-2.95) was associated with increased risk of opioid toxicity compared to codeine. An analysis restricted to events leading to deaths, hospitalizations or escalation of care showed increased risk with meperidine (IRR=3.43, 95% CI 1.05-11.24) and tramadol (IRR=4.73, 95% CI 2.07-10.82).

Conclusion:  We studied a cohort of children without serious underlying conditions who received opioid analgesics for mostly minor and self-limited outpatient disorders. The cumulative incidence of opioid toxicity was 33.2/100,000 prescriptions at 17 days of follow-up. The use of tramadol, oxycodone, and meperidine, and higher doses of opioids in general increased the risk of toxicity.


Disclosure: C. P. Chung, None; S. T. Callahan, None; W. Cooper, None; W. Dupont, None; K. Murray, None; K. Hall, None; J. A. Dudley, None; C. M. Stein, None; W. Ray, None.

To cite this abstract in AMA style:

Chung CP, Callahan ST, Cooper W, Dupont W, Murray K, Hall K, Dudley JA, Stein CM, Ray W. Opioid Prescriptions and Adverse Reactions in Children and Adolescents without Serious Diseases [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/opioid-prescriptions-and-adverse-reactions-in-children-and-adolescents-without-serious-diseases/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/opioid-prescriptions-and-adverse-reactions-in-children-and-adolescents-without-serious-diseases/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology